ITMCTR1900002856尚未招募4 期
A multi - center, randomized, double-blind, parallel-controlled trial for the efficacy and safety of Lian-hua Qing-wen granules in the treatment of influenza in children
First Teaching Hospital of Tianjin University of TCM0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 3 至 14（—）
- 性别
- All
入选标准
- •(1) Patients meet the clinical diagnostic criteria for influenza;
- •(2) Diagnosed as heat attack lung TCM syndrome;
- •(3) Aged 3-14 years old;
- •(4) The course of fever <=48 hours, maximum axillary temperature >=38.5 degree C;
- •(5) Tested positive for influenza infection using a rapid influenza diagnostic test (RIDT);
- •(6) the informed consent process is in accordance with the provisions, and the legal representative or(and) the children (>=8 years old) co-sign the informed consent.
排除标准
- •(1) Severe or critical cases of influenza, or diagnosed as pharyngeal binding membrane fever, herpetic pharyngitis, suppurative tonsillitis, etc.;
- •(2) Patient with influenza complications,such as sinusitis, otitis media, bronchitis and pneumonia;
- •(3) Antiviral drugs were used within 48 hours before the visit;
- •(4) Received influenza vaccine within 12 months prior to the start of the trial;
- •(5) Recieving systemic steroid therapy or other immunosuppressive therapy;
- •(6) Patient has history of epilepsy or febrile convulsion;
- •(7) Severe malnutrition, rickets and severe primary diseases of the heart, brain, liver, kidney and hematopoietic system;
- •(8) Allergic to the ingredients of experimental drugs;
- •(9) according to the judgment of the researcher, other diseases or conditions, such as unstable living environment and inconvenient transportation, which may reduce the possibility or complicate the inclusion, may easily lead to loss of access.
研究者
相似试验
已完成
不适用
A multi center, randomized, double-blind, parallel, factorial design, therapeutic confirmatory(phase III) study to evaluate the efficacy and safety of combination of Rosuvastatin and Ezetimibe in patients with primary hypercholesterolemiaDiseases of the circulatory systemKCT0001831Daegu Catholic Univercity Medical Center420
招募中
不适用
HIPER-500KCT0002734Samsung Medical Center120
进行中（未招募）
不适用
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 17.0Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021871-10-ATInnovacell Biotechnologie AG - Life Science Center Innsbruck372
进行中（未招募）
不适用
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 14.1Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021871-10-BGInnovacell Biotechnologie AG - Life Science Center Innsbruck372
进行中（未招募）
不适用
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 17.1Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021871-10-DEInnovacell Biotechnologie AG - Life Science Center Innsbruck372